Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) shares fell 6.6% during trading on Wednesday . The company traded as low as $70.73 and last traded at $70.78, with a volume of 679,412 shares changing hands. The stock had previously closed at $75.79.

A number of research firms have recently commented on ALNY. Goldman Sachs Group Inc. restated a “neutral” rating and set a $65.00 price target (up from $63.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Tuesday, August 9th. Cowen and Company reiterated a “buy” rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a research report on Sunday, August 7th. Needham & Company LLC reiterated a “buy” rating and issued a $152.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, August 5th. Finally, JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $113.62.

The stock’s market capitalization is $6.07 billion. The company’s 50-day moving average is $69.27 and its 200 day moving average is $63.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. During the same quarter in the previous year, the business earned ($0.85) earnings per share. The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.09 million. The firm’s revenue for the quarter was up .2% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals Inc. will post ($4.69) EPS for the current year.

In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A hedge fund recently raised its stake in Alnylam Pharmaceuticals stock. BlackRock Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 8.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 179,529 shares of the biopharmaceutical company’s stock after buying an additional 13,612 shares during the period. BlackRock Advisors LLC owned 0.21% of Alnylam Pharmaceuticals worth $16,901,000 as of its most recent SEC filing.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.